Impact of Moderate Sedation versus Monitored Anesthesia Care on Outcomes and Cost of Endobronchial Ultrasound Transbronchial Needle Aspiration
Table 1
Patients and procedure characteristics.
MS
MAC
P Value
Number of patients
99
99
Age (Mean/SD)
62.45 (14.43)
60.38 (18.81)
0.387
Sex - Male (n/)
46 (46.5%)
44 (44.4%)
0.775
EBUS-TBNA diagnosis (n/)
0.536
Adenocarcinoma
29 (29.3%)
24 (24.2%)
Squamous Cell Carcinoma
9 (9.1%)
15 (15.2%)
Sarcoid
11(11.1%)
8 (8.1%)
Lymphoma
5 (5.1%)
8 (8.1%)
Small Cell Carcinoma
10(10.1%)
5 (5.1%)
Other
6 (6.1%)
6 (6.1%)
Nondiagnostic/normal
29 (29.3%)
33 (33.3%)
Procedure Time in minutes (Median/IQR)
30 (23 – 40)
30 (22 – 38)
0.630
Sedative dose
Fentanyl (Median/IQR)
100 (100 – 125)
50 (8 - 60)
< 0.001
Midazolam (Mean/SD)
4.84 (1.97)
1.25 (0.92)
<0.001
Lymph node station sampled
Total Lymph nodes (n/)
226
204
2R
2 (0.9%)
3 (1.5%)
2L
0 (0%)
1 (0.5%)
3P
0 (0%)
1 (0.5%)
4R
57 (25.2%)
42 (20.6%)
4L
16 (7.1%)
11 (5.4%)
7
74 (32.7%)
66 (32.4%)
8
0 (0%)
2 (1%)
10R
10 (4.4%)
9 (4.4%)
10L
1 (0.4%)
2 (1%)
11R
41 (18.1%)
31 (15.2%)
11L
20 (8.8%)
32 (15.7%)
12R
5 (2.2%)
4 (2%)
Number of LN sampled/patient (Mean/SD)
2.29 (0.87)
2.06 (0.77)
0.048
Size of LN (Mean/SD)
18.88 (7.41)
18.03 (7.82)
0.440
Number of passes per LN
1.6 (0.6)
2.24 (0.91)
<0.001
The diagnoses that were included in “Other” were 6 breast cancers, 2 esophageal cancers, and one of each of the following: CLL, colon cancer, large cell carcinoma, or mesothelioma. MS: moderate sedation; MAC: monitored anesthesia care; LN: lymph node.
